1.03BMarket Cap-20557P/E (TTM)
7.280High7.030Low786.27KVolume7.280Open7.320Pre Close5.63MTurnover0.61%Turnover RatioLossP/E (Static)142.99MShares10.05052wk High2.82P/B925.13MFloat Cap4.71052wk Low--Dividend TTM128.58MShs Float33.972Historical High--Div YieldTTM3.42%Amplitude1.000Historical Low7.159Avg Price1Lot Size
Aurinia Pharmaceuticals Stock Forum
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Aurinia Presents New Data Highlighting Real-World Utilization and Value of LUPKYNIS® in Treating Lupus Nephritis at American Society of Nephrology Kidney Week 2024
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Key highlights include:
...
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals (AUPH.US)$
No comment yet